Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
Toxicology Mechanisms and Methods|March 7, 2023
Comparison of different QT correction methods for nonclinical safety assessment in ketamine-anesthetized Indian rhesus monkeys (<i>Macaca mulatta</i>)Laxit K Bhatt, Chitrang R Shah, Rajesh J Patel, et al.
Bioorganic & Medicinal Chemistry Letters|July 1, 2008
Facile synthesis, ex-vivo and in vitro screening of 3-sulfonamide derivative of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide (SR141716) a potent CB1 receptor antagonistBrijesh Kumar Srivastava, Rina Soni, Jayendra Z Patel, et al.
ACS Medicinal Chemistry Letters|April 16, 2020
Discovery of <i>N</i>-Cyano-sulfoximineurea Derivatives as Potent and Orally Bioavailable NLRP3 Inflammasome InhibitorsSameer Agarwal, Santosh Sasane, Hardik A Shah, et al.
Regulatory Toxicology and Pharmacology : RTP|August 27, 2025
Preclinical safety, tolerability and pharmacokinetics of a novel cyclobenzaprine hydrochloride nasal sprayChitrang R Shah, Sudhir R Patel, Laxit K Bhatt, et al.
Laboratory Animal Research|November 11, 2022
Hematological and biochemical reference intervals of wild-caught and inhouse adult Indian rhesus macaques (Macaca mulatta)Niraj A Shah, Laxit K Bhatt, Rajesh J Patel, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 30, 2025
Discovery of ZYDG2: A potent, selective, and safe GPR40 agonist for treatment of type 2 diabetesMukul R Jain, Suresh R Giri, Chitrang J Trivedi, et al.
International Journal of Toxicology|December 18, 2023
A Retrospective Comparison of Electrocardiographic Parameters in Ketamine and Tiletamine-Zolazepam Anesthetized Indian Rhesus Monkeys (<i>Macaca mulatta</i>)Laxit K Bhatt, Chitrang R Shah, Shital D Patel, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 23, 2017
Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH modelsMukul R Jain, Suresh R Giri, Bibhuti Bhoi, et al.
Clinical Pharmacology in Drug Development|September 6, 2022
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First-in-Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose)Deven V Parmar, Kevinkumar A Kansagra, Taufik Momin, et al.
Journal of Medicinal Chemistry|November 6, 2007
Diaryl dihydropyrazole-3-carboxamides with significant in vivo antiobesity activity related to CB1 receptor antagonism: synthesis, biological evaluation, and molecular modeling in the homology modelBrijesh Kumar Srivastava, Amit Joharapurkar, Saurin Raval, et al.
Pageof 10